Year: 2020

Inlösen av optionsprogram i Nanologica AB

Delar av Nanologicas optionsprogram 2018/21 har lösts in av optionsinnehavarna, vilket medför en ökning av antalet aktier i bolaget med 77 773 till 27 776 850 aktier. Aktiekapitalet ökar som en följd av detta med 31 886,93 SEK till 11 389 278,16 SEK.   Vid Nanologicas årsstämma den 31 maj 2018 beslutades om att inrätta ett incitamentsprogram om maximalt 484 883 teckningsoptioner för bolagets anställda. Varje teckningsoption ger rätten att teckna en aktie i bolaget till en teckningskurs motsvarande

Read more »

Publication on Empty Particles for the Treatment of ALS

The publication “Empty mesoporous silica particles significantly delay disease progression and extend survival in a mouse model of ALS” has been published in Nature Research Scientific Reports, Nov 26, 2020. The publication relates to Nanologica’s patent application “Porous particles for use in treatment, prevention and/or postponement of degeneration of neurons and glia” that became public on Oct. 15, and demonstrates how empty porous silica particles has the potential of delaying the disease progression and extending

Read more »

Biotechgate Digital Partnering Nov 23-26

Nov 23-26, Nanologica will take part of the Biotechgate Digital Partnering event. This is a virtual business development event during four days with the aim of partnering and establishing new global connections. The Biotechgate Digital Partnering is designed to support the business development of Biotech, Medtech and Pharma companies through pre-booked one-on-one meetings.

Read more »